<DOC>
	<DOCNO>NCT01020968</DOCNO>
	<brief_summary>This study design assess safety profile efficacy cardiac repair cell ( CRCs ) administer via catheter treat patient dilate cardiomyopathy ( DCM ) .</brief_summary>
	<brief_title>Use Ixmyelocel-T ( Formerly Catheter-based Cardiac Repair Cell CRC ) Treatment Patients With Heart Failure Due Dilated Cardiomyopathy</brief_title>
	<detailed_description>Heart failure remain major public health problem , affect 5 million patient US , 550,000 new diagnosis make year ( Hunt SA ; et al. , 2005 ) . Heart failure lead cause hospitalization person 65 year age cost exceed $ 29 billion annually . Prognosis poor patient hospitalize heart failure . The mortality risk heart failure hospitalization 11.3 % 30 day , 33.1 % 1 year well 50 % within 5 year ( Hunt SA ; et al. , 2005 ) . These number emphasize need develop implement effective treatment manage heart failure . Aastrom target subset heart failure patient population , namely diagnose dilate cardiomyopathy . The World Health Organization ( WHO ) defines dilate cardiomyopathy ( DCM ) cardiac condition wherein ventricular chamber exhibit increase diastolic systolic volume low ( &lt; 40 % ) ejection fraction ( Manolio TA ; et al. , 1992 ; Towbin JA ; et al. , 2006 ) . DCM report affect 108,000 150,000 patient United States ( Richardson P ; et al. , 1996 ; Towbin JA ; et al. , 2006 ) . This study prospective , stratify , randomize , open-label , control , multi-center study assess safety profile efficacy CRCs administer via catheter treat patient DCM . Two stratum use : ischemic ( IDCM ) non-ischemic ( NIDCM ) . Within stratum , patient randomize receive either CRC treatment control 2:1 ratio ( 8 patient per CRC treatment group 4 patient per control group ) . It enroll total 24 patient 2 site U.S .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Diagnosis ischemic nonischemic dilate cardiomyopathy accord WHO criteria . Ischemic : DCM patient history myocardial infarction evidence clinically significant ( &gt; /= 70 % narrow major epicardial artery ) coronary artery disease . Nonischemic : Dilation impaired contraction leave ventricle ventricle idiopathic , familial/genetic , viral and/or immune , toxic origin , associate recognize cardiovascular disease degree myocardial dysfunction explain normal loading condition extent ischemic damage . No cardiac surgery percutaneous cardiac intervention likely produce clinical improvement , determine interventional cardiologist ( PTCA ) cardiothoracic surgeon ( CABG ) . This condition satisfy patient w/chronic ischemic disease previously successfully revascularized fail show clinical improvement . All patient candidate revascularization ineligible participation . LVEF &lt; /= 30 % echocardiogram within 30 day prior randomization . Symptomatic heart failure NYHA class III IV . Able comply schedule visit cardiac outpatient clinic . Able tolerate study procedure , include bone marrow aspiration , cardiac CT , metabolic stress test,6 minute walk test . Males female , 1886 year age . Life expectancy 6 month opinion investigator . Able give inform consent . Normal organ marrow function ( Leukocytes &gt; /= 3,000/microgram , Absolute neutrophil count &gt; /= 1,500/microgram , Platelets &gt; /= 140,000/microgram , AST ( SGOT ) /ALT ( SGPT ) &lt; /= 2.5 X institutional standard range Creatinine &lt; /= 2.5 mg/dL ) . Controlled blood pressure ( systolic blood pressure &lt; /= 140 ; diastolic blood pressure &lt; /= 90 mmHg ) establish antihypertensive therapy necessary prior entry study . Stable , standard medical therapy DCM least 1 month NO new medication treat disease introduce last 3 month . Standard medical therapy include : Placement AICD unless contraindicate ( refusal AICD consider valid contraindication ) , use ACE inhibitor and/or AT1 receptor blocker well loop diuretic unless contraindicate , depend type heart failure associate disease , standard therapy may also include use vasodilator , beta blocker , digoxin , aldosterone medication . Preexisting condition adequately control opinion investigator . Fertile patient must agree use appropriate form contraception participate study . Severe primary valvular heart disease include , limited , aortic valve stenosis insufficiency . Known history COPD define Gold stage IIB ( FEV1/FVC &lt; 70 % 30 % &lt; /=FEV1 &lt; 50 % predict , without chronic symptom cough , sputum production , dyspnea ) severe restrictive pulmonary disease . Known history primary pulmonary hypertension . VAD implantation . Myocardial infarction within 4 week prior randomization . History lifethreatening ventricular arrhythmia , except AICD implant . Unstable angina , characterize increasingly frequent episode modest exertion rest , worsen severity , prolonged duration . Patients high risk complication due injection procedure ( e.g . patient severe peripheral atherosclerotic disease allow advancement catheter ; patient prosthetic aortic mitral valve ; patient LV thrombus aneurysm ; patient aortic dissection aneurysm , etc. ) . Patients w/poorly control diabetes mellitus ( HbAlc &gt; 9.0 % ) . Patients receive treatment hematopoietic growth factor ( e.g . EPO , GCSF ) . Patients require uninterruptible anticoagulation therapy ( e.g . warfarin ) stop 72 hour prior bone marrow aspiration intramyocardial injection ; OR patient receive antiplatelet therapy ( e.g . clopidogrel ) stop 7 day prior bone marrow aspiration transendocardial injection , unless contraindicate . Known cancer undergo treatment include chemotherapy radiation . Patients require continuous , systemic , high dose corticosteroid therapy ( 7.5 mg/day ) within 1 month aspiration 6 month injection procedure . End stage renal disease require dialysis . Patients pregnant lactating ; positive hCG History alcohol consumption regularly exceed equivalent 2 drinks/day ( 1 drink = 5 oz wine 12 oz [ 360mL ] beer 1.5 oz [ 45mL ] ) hard liquor history illicit drug use w/in 6 month screen . Known allergy protein product ( horse bovine serum , porcine trypsin ) use exvivo cell production process . BMI 40 Kg/m2 great . Patients receive experimental medication participate another clinical study within 30 day screen . HIV syphilis , positive time screen . Active Hepatitis B Hepatitis C infection time screen . Patient determine unsuitable cellular therapy , opinion investigator sponsor . Patients receive antiangiogenic drug ( e.g . antiVEGF ) . Known allergy sensitivity contrast agent use image procedure . Minimum LV wall thickness le 6mm determined ECHO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ischemic Dilated Cardiomyopathy</keyword>
	<keyword>Non-Ischemic Dilated Cardiomyopathy</keyword>
	<keyword>ixmyelocel-T</keyword>
</DOC>